🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ohad S. Bentur

Summit Medical Group (United States)

ORCID: 0000-0002-5976-7121
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist”.

Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist

TH Open(2021)10.1055/s-0041-1732343
N/A
0DataRank · unranked
9 citations

Jihong Li, Caroline S. Jiang, Linda H. Martin, Dean J. Kereiakes, Barry S. Coller +1 more

CTSA pharmacies: Contribution to research and public health during the COVID-19 pandemic

Journal of Clinical and Translational Science(2021)10.1017/cts.2021.13
N/A
0DataRank · unranked
4 citations

Ohad S. Bentur, Ian C. MacArthur, Anna S. Bartoo, Donna Capozzi, Jason Albert Christensen +4 more

Serum aldosterone and urine electrolytes dynamics in response to DASH diet intervention – An inpatient mechanistic study

Journal of Clinical and Translational Science(2022)10.1017/cts.2022.394
N/A
0DataRank · unranked
4 citations

Adam Qureshi, Ohad S. Bentur, Andrea Ronning, Jonathan N. Tobin, Rhonda G. Kost +1 more

Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study

American Heart Journal(2023)10.1016/j.ahj.2023.04.009
N/A
0DataRank · unranked
12 citations

Willem L. Bor, Abi Selvarajah, Kai Zheng, A. Hack, C. Michael Gibson +6 more

855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE

Hematological Oncology(2025)10.1002/hon.70096_855
N/A
0DataRank · unranked
0 citations

Eva Domingo‐Doménech, David Sidransky, Ohad S. Bentur, Pier Luigi Zinzani, Kate Cwynarski